Indications for DDAVP RHINAL TUBE:
Central (cranial) diabetes insipidus. Temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.
Individualize. 10–40mcg intranasally in 1–3 divided doses; usually 20mcg in two divided doses.
<3months: not recommended. Individualize. ≥3months: 5–30mcg daily intranasally in 1–2 divided doses.
DDAVP RHINAL TUBE Contraindications:
Moderate to severe renal impairment (CrCl <50mL/min). Hyponatremia, or history of.
DDAVP RHINAL TUBE Warnings/Precautions:
Monitor fluid intake, urine volume and osmolality. Fluid/electrolyte imbalance (eg, cystic fibrosis). Habitual or psychogenic polydipsia. Coronary artery insufficiency. Hypertension. Inj: Predisposition to thrombosis. Nasal mucosal abnormalities (nasal forms). Young children. Elderly. Pregnancy. Nursing mothers.
DDAVP RHINAL TUBE Classification:
DDAVP RHINAL TUBE Interactions:
Caution with other pressor agents, drugs that may increase the risk of water intoxication with hyponatremia (eg, tricyclic antidepressants, SSRIs, chlorpromazine, opiates, NSAIDs, lamotrigine, carbamazepine). Possible convulsions with oxybutynin, imipramine.
Headache, nausea, flushing, abdominal cramps, vulval pain, water intoxication, hyponatremia, nasal congestion or rhinitis (nasal forms), inj site reaction; rare: changes in BP, severe allergic reactions, seizures in children from plasma hypoosmolality, thrombotic events (inj).
Tabs—100; Rhinal tube—2.5mL (w. 2 rhinal tubes); Amp (1mL)—10; Multi-dose vial (10mL)—1; Nasal spray—5mL (50 sprays)